Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0AZLE)

Drug Name

WY-46016 Drug Info

Synonyms

104325-55-5; 3-(2-Quinolinylmethoxy)benzeneacetic acid; Wy-46016; WY-46,016; AC1L2TZC; 2-[3-(quinolin-2-ylmethoxy)phenyl]acetic acid; [3-(Quinolin-2-ylmethoxy)-phenyl]-acetic acid; CHEMBL310611; SCHEMBL9053241; CTK8G4858; DTXSID00146391; VTTJDSVAGYOMKY-UHFFFAOYSA-N; ZINC5162878; 3-(2-Quinolinylmethoxy)phenylacetic acid; 3-[(2-Quinolinyl)methoxy]benzeneacetic acid; Benzeneacetic acid, 3-(2-quinolinylmethoxy)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 128543
CAS Number: CAS 104325-55-5
TTD Drug ID: DM0AZLE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Montelukast	DMD157S	Allergic asthma	CA23.0	Approved	[2]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[3]
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[4]
Cinalukast	DMFIC0M	Asthma	CA23	Approved	[5]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[6]
BAY-X-7195	DM2XE80	Asthma	CA23	Phase 2	[7]
Masilukast	DMDTI0L	Asthma	CA23	Phase 2	[8]
LM-1507.NA	DMW6VA0	Asthma	CA23	Phase 2	[9]
Iralukast	DMQ3RWN	Asthma	CA23	Phase 2	[10]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene CysLT1 receptor (CYSLTR1)	TTGKOY9	CLTR1_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides.Potent orally active leukotriene D4 antagonists of novel structure.J Med Chem.1990 Jan;33(1):240-5.
2	Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
3	Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
4	Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
5	Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
6	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
7	The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
8	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9	Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
10	Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
11	In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.